AIM: This study aims to investigate the clinical and demographic factors influencing gentamicin pharmacokinetics in a large cohort of unselected premature and term newborns and to evaluate optimal regimens in this population. METHODS: All gentamicin concentration data, along with clinical and demographic characteristics, were retrieved from medical charts in a Neonatal Intensive Care Unit over 5 years within the frame of a routine therapeutic drug monitoring programme. Data were described using non-linear mixed-effects regression analysis ( nonmem®). RESULTS: A total of 3039 gentamicin concentrations collected in 994 preterm and 455 term newborns were included in the analysis. A two compartment model best characterized gentamicin disposition. The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l. Body weight, gestational age and post-natal age positively influenced CL. Dopamine co-administration had a significant negative effect on CL, whereas the influence of indomethacin and furosemide was not significant. Both body weight and gestational age significantly influenced Vc . Model-based simulations confirmed that, compared with term neonates, preterm infants need higher doses, superior to 4 mg kg(-1) , at extended intervals to achieve adequate concentrations. CONCLUSIONS: This observational study conducted in a large cohort of newborns confirms the importance of body weight and gestational age for dosage adjustment. The model will serve to set up dosing recommendations and elaborate a Bayesian tool for dosage individualization based on concentration monitoring.
AIM: This study aims to investigate the clinical and demographic factors influencing gentamicin pharmacokinetics in a large cohort of unselected premature and term newborns and to evaluate optimal regimens in this population. METHODS: All gentamicin concentration data, along with clinical and demographic characteristics, were retrieved from medical charts in a Neonatal Intensive Care Unit over 5 years within the frame of a routine therapeutic drug monitoring programme. Data were described using non-linear mixed-effects regression analysis ( nonmem®). RESULTS: A total of 3039 gentamicin concentrations collected in 994 preterm and 455 term newborns were included in the analysis. A two compartment model best characterized gentamicin disposition. The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l. Body weight, gestational age and post-natal age positively influenced CL. Dopamine co-administration had a significant negative effect on CL, whereas the influence of indomethacin and furosemide was not significant. Both body weight and gestational age significantly influenced Vc . Model-based simulations confirmed that, compared with term neonates, preterm infants need higher doses, superior to 4 mg kg(-1) , at extended intervals to achieve adequate concentrations. CONCLUSIONS: This observational study conducted in a large cohort of newborns confirms the importance of body weight and gestational age for dosage adjustment. The model will serve to set up dosing recommendations and elaborate a Bayesian tool for dosage individualization based on concentration monitoring.
Authors: Jose M Lopez-Novoa; Yaremi Quiros; Laura Vicente; Ana I Morales; Francisco J Lopez-Hernandez Journal: Kidney Int Date: 2010-09-22 Impact factor: 10.612
Authors: Spyridon Pagkalis; Elpis Mantadakis; Michael N Mavros; Christina Ammari; Matthew E Falagas Journal: Drugs Date: 2011-12-03 Impact factor: 9.546
Authors: Roosmarijn F W De Cock; Karel Allegaert; Michiel F Schreuder; Catherine M T Sherwin; Matthijs de Hoog; Johannes N van den Anker; Meindert Danhof; Catherijne A J Knibbe Journal: Clin Pharmacokinet Date: 2012-02-01 Impact factor: 6.447
Authors: Yuma A Bijleveld; Maria E van den Heuvel; Caspar J Hodiamont; Ron A A Mathôt; Timo R de Haan Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191
Authors: Tamara van Donge; Marc Pfister; Julia Bielicki; Chantal Csajka; Frederique Rodieux; John van den Anker; Aline Fuchs Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: Yuma A Bijleveld; Timo R de Haan; Hanneke J H van der Lee; Floris Groenendaal; Peter H Dijk; Arno van Heijst; Rogier C J de Jonge; Koen P Dijkman; Henrica L M van Straaten; Monique Rijken; Inge A Zonnenberg; Filip Cools; Alexandra Zecic; Debbie H G M Nuytemans; Anton H van Kaam; Ron A A Mathot Journal: Br J Clin Pharmacol Date: 2016-03-10 Impact factor: 4.335
Authors: Mihai Puia-Dumitrescu; Olivia M Bretzius; Nia Brown; James A Fitz-Henley; Rebecca Ssengonzi; Caroline S Wechsler; Keyaria D Gray; Daniel K Benjamin; P Brian Smith; Reese H Clark; Daniel Gonzalez; Christoph P Hornik Journal: J Pediatr Date: 2018-09-21 Impact factor: 4.406
Authors: Eva Germovsek; Alison Kent; Tuuli Metsvaht; Irja Lutsar; Nigel Klein; Mark A Turner; Mike Sharland; Elisabet I Nielsen; Paul T Heath; Joseph F Standing Journal: Antimicrob Agents Chemother Date: 2016-07-22 Impact factor: 5.191